New hope for tough cancers: first human tests begin
NCT ID NCT06260774
Summary
This early-stage study is testing a new drug called TTX-MC138 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. Participants will receive the drug through an IV every 28 days and will be closely monitored for side effects and any signs that the tumor is shrinking or stopping its growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77230, United States
-
Mary Crowley Cancer Center
Dallas, Texas, 75230, United States
-
Next Oncology
Fairfax, Virginia, 22031, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
Conditions
Explore the condition pages connected to this study.